Chronic Pain
Conditions
Brief summary
This is a study designed to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain.
Detailed description
The aim of this trial is to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain. Participants will include individuals with chronic pain, who will be randomized into one of two intervention conditions: low THC/high CBD or placebo. In addition to receiving CBD or placebo, participants also will complete symptom assessments of chronic pain data (intensity, quality, interference/disability) throughout the study. These measures will be gathered prior to and following the fifth doses (dosing will occur once per day for five days) of CBD or placebo. A secondary objective will be to examine the association between clinical and inflammatory markers.
Interventions
DRUGCannabidiol
500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
DRUGPlacebo
Placebo
Sponsors
University of Utah
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18-50 yrs. * Chronic musculoskeletal and joint pain for at least 3 months or longer. * Participants must live within a 60 mile radius of Salt Lake City, Utah to be eligible.
Exclusion criteria
* Current or past neurological illness. * Substance abuse or dependence within the prior 90 days. * Contraindication to brain MRI. * Type I and type II diabetes. * Unstable medical conditions. * Consumption of more than 2 drinks of alcohol per night. * Current pregnancy or planning to become pregnant or breastfeeding. * History of seizures or head trauma at PI discretion. * Active or history of major mental illness * Use of opioid medications in the past 30 days. * LFT results 3 times greater than the upper limit of normal at the screening. * Participants may be excluded if the PI feels they do not meet safety criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neurochemical Brain Changes | 5 Days | Participants will undergo MRS scanning to assess neurochemical shifts from the baseline visit (day 1) to the visit five (day 5) in order to determine whether CBD, or Placebo will result in changes to neurochemical ratios in select brain regions. Neurotransmitter levels such as BABA and N-Acetylaspartate will be collected and compared pre and post study drug administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Improvement | 7 Days | Using baseline assessment measures gathered at visit 0 (Screening), assessments collected at visits 1-5 and follow-up will be used to determine whether the administration of CBD or placebo will improve pain relief in individuals with chronic pain. We will measure pain intensity with a visual analog scale from (0-10) with 10 being the worst pain imaginable. We will also measure Objective pain thresholds with a pressure algometer. This is a device that applies pressure to the participants finger until they say stop. The pressure range is 0-50 foot pounds of force. |
Countries
United States
Outcome results
None listed